Literature DB >> 22005052

Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.

Rafael G Dos Santos1, Marta Valle, José Carlos Bouso, Josep F Nomdedéu, José Rodríguez-Espinosa, Ethan H McIlhenny, Steven A Barker, Manel J Barbanoj, Jordi Riba.   

Abstract

Ayahuasca is an Amazonian psychotropic plant tea combining the 5-HT2A agonist N,N-dimethyltryptamine (DMT) and monoamine oxidase-inhibiting β-carboline alkaloids that render DMT orally active. The tea, obtained from Banisteriopsis caapi and Psychotria viridis, has traditionally been used for religious, ritual, and medicinal purposes by the indigenous peoples of the region. More recently, the syncretistic religious use of ayahuasca has expanded to the United States and Europe. Here we conducted a double-blind randomized crossover clinical trial to investigate the physiological impact of ayahuasca in terms of autonomic, neuroendocrine, and immunomodulatory effects. An oral dose of encapsulated freeze-dried ayahuasca (1.0 mg DMT/kg body weight) was compared versus a placebo and versus a positive control (20 mg d-amphetamine) in a group of 10 healthy volunteers. Ayahuasca led to measurable DMT plasma levels and distinct subjective and neurophysiological effects that were absent after amphetamine. Both drugs increased pupillary diameter, with ayahuasca showing milder effects. Prolactin levels were significantly increased by ayahuasca but not by amphetamine, and cortisol was increased by both, with ayahuasca leading to the higher peak values. Ayahuasca and amphetamine induced similar time-dependent modifications in lymphocyte subpopulations. Percent CD4 and CD3 were decreased, whereas natural killer cells were increased. Maximum changes occurred around 2 hours, returning to baseline levels at 24 hours. In conclusion, ayahuasca displayed moderate sympathomimetic effects, significant neuroendocrine stimulation, and a time-dependent modulatory effect on cell-mediated immunity. Future studies on the health impact of long-term ayahuasca consumption should consider the assessment of immunological status in regular users.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22005052     DOI: 10.1097/JCP.0b013e31823607f6

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  34 in total

1.  Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users.

Authors:  José Carlos Bouso; Josep Maria Fábregas; Rosa Maria Antonijoan; Antoni Rodríguez-Fornells; Jordi Riba
Journal:  Psychopharmacology (Berl)       Date:  2013-06-21       Impact factor: 4.530

Review 2.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

Review 3.  Neurotoxicology Syndromes Associated with Drugs of Abuse.

Authors:  Rachel A Caplan; Jonah P Zuflacht; Jed A Barash; Corey R Fehnel
Journal:  Neurol Clin       Date:  2020-11       Impact factor: 3.806

4.  Plants with Anti-Addictive Potential.

Authors:  Eduardo Luis Konrath; Marcelo Dutra Arbo; Bruno Dutra Arbo; Mariana Appel Hort; Elaine Elisabetsky; Mirna Bainy Leal
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?

Authors:  Benjamin J Malcolm; Kelly C Lee
Journal:  Ment Health Clin       Date:  2018-03-23

Review 6.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

7.  Pharmacology of ayahuasca administered in two repeated doses.

Authors:  Rafael G Dos Santos; Eva Grasa; Marta Valle; Maria Rosa Ballester; José Carlos Bouso; Josep F Nomdedéu; Rosa Homs; Manel J Barbanoj; Jordi Riba
Journal:  Psychopharmacology (Berl)       Date:  2011-08-13       Impact factor: 4.530

Review 8.  A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.

Authors:  Ede Frecska; Attila Szabo; Michael J Winkelman; Luis E Luna; Dennis J McKenna
Journal:  J Neural Transm (Vienna)       Date:  2013-04-26       Impact factor: 3.575

Review 9.  Neuropharmacology of N,N-dimethyltryptamine.

Authors:  Theresa M Carbonaro; Michael B Gatch
Journal:  Brain Res Bull       Date:  2016-04-25       Impact factor: 4.077

Review 10.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.